Joaquin Duato

Stories

First oral biologic for psoriasis reaches patients, opening new front in autoimmune treatment

Positioning ICOTYDE as key growth driver for 2026

For two decades, treating moderate-to-severe psoriasis required needles — self-injected drugs or clinic infusions many patients refused or abandoned. On March 18, 2026, the FDA approved ICOTYDE, a once-daily pill that blocks the IL-23 receptor like injectable biologics. In trials of roughly 2,500 patients, about 70 percent achieved clear or almost clear skin at 16 weeks, with side effects within 1.1 percentage points of placebo.

Updated May 30